TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03503942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
Study: NCT00558675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: single intravenous infusion of 1 x 10\^9 AlloStim cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7 and day 14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Intravenous infusion of 1 x 10\^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10\^8 AlloStim on day 7, day 14 and day 21
Study: NCT01784705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial bright light therapy
Description: The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial placebo treatment
Description: The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
Study: NCT02316236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: an alpha-2 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: an alpha-2 receptor agonist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loading dose
Description: 0.8ug/kg of dexmedetomidine is given in 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sustaining dose
Description: 0.4ug/kg/min of dexmedetomidine is given
Study: NCT02480621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine with Bupivacaine
Description: Pain medications injected locally during surgery around affected ankle.
Study: NCT03808285

Intervention type: OTHER
Intervention: mandibular osteomylitis
Study: NCT01339650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-767
Description: ABT-767 once or twice daily for a 28 day cycle
Study: NCT02405494

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 1

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 2

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 3

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 4

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 5

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 6

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 7

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 8

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beverage 9
Study: NCT01817764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol
Description: Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/salmeterol
Description: Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
Study: NCT00788008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalation anesthesia with isoflurane vs. TIVA with propofol
Description: variable depending upon patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalation anesthesia with isoflurane vs. TIVA with propofol
Description: variable depending upon patient
Study: NCT01184781

Intervention type: DEVICE
Group type: OTHER
Intervention: Comparison of capsule endoscopy Pillcam II™ versus colonoscopy
Description: On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
Study: NCT03970252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT03950492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Simulator
Description: This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
Study: NCT04670679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally
Study: NCT03970252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04670679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered via intravenous infusion
Study: NCT01342367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
Study: NCT01527942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intravenous Acetaminophen 1,000 mg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
Study: NCT04670679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via intravenous infusion
Study: NCT02799082

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-200 ALA
Description: topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
Study: NCT02621762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Magnesium in dialysate increased

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Magnesium in dialysate increased

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bicarbonate
Description: Bicarbonate in dialysate increased

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bicarbonate
Description: Bicarbonate in dialysate increased
Study: NCT01702233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S inj
Description: Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortecortin/Dexamethasone 8 mg/2 ml inj
Description: Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline inj
Description: Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
Study: NCT03779529

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: Intervention includes dosage and amount of biophenols administered daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: Intervention includes dosage and amount of biophenols administered daily
Study: NCT02242786

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Study: NCT03239652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taiwan ACE Beads
Description: Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
Study: NCT02266238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSA guided percutaneous balloon dilatation
Description: Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous balloon dilatation
Description: Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction
Description: Direct surgery to reconstruction the AVF lumen.
Study: NCT03322202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
Study: NCT00856492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study: NCT01111773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heated Lidocaine and Tetracaine Patch
Description: Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
Study: NCT01938638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1143572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1143572
Study: NCT01129557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study: NCT03596957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: At baseline the tolvaptan dosing will start with daily morning and afternoon doses of 45 mg and 15 mg respectively, with weekly increases to 60 mg and 30 mg and then to 90 mg and 30 mg according to subject tolerability
Study: NCT04119297

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: * Routine care was applied to the periorbital area by clinical nurses.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold gel pack
Description: * Cold application was applied to the periorbital area for 20 minutes per hour beginning 3rd hour following craniotomy, except from 10pm-7 am, and for three days using gel pack cooled to -14ºC.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparinoids Topical Cream
Description: * Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale
Study: NCT02248844

Intervention type: BIOLOGICAL
Intervention: Botulinum Toxin Type A
Description: Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
Study: NCT01310842

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.

Intervention type: DRUG
Intervention: Nicotine Patch Therapy
Description: 4 weeks of nicotine patch therapy

Intervention type: DRUG
Intervention: Nicotine Patch Therapy
Description: 4 weeks of nicotine patch therapy

Intervention type: BEHAVIORAL
Intervention: Counseling Sessions
Description: 5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.

Intervention type: BEHAVIORAL
Intervention: Counseling Sessions
Description: 5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
Study: NCT00372684

Intervention type: GENETIC
Intervention: with severe malaria hospitalized in ICU
Description: with severe malaria hospitalized in ICU

Intervention type: GENETIC
Intervention: with uncomplicated malaria
Description: with uncomplicated malaria
Study: NCT00669669

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D conformal IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous in vitro-treated peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous in vitro-treated peripheral blood stem cell transplant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo 3D conformal IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-Benzylguanine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT00860795

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea
Description: Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 25 ml daily in 2 divided doses for 10 days
Study: NCT03452670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Group
Description: Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Group
Description: The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
Study: NCT02242812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01238172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary education and counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prostate cancer foundation booklet
Study: NCT01387672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates (NABT Main trial)
Description: nitroglycerin; isosorbide mononitrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates (NABT Main trial)
Description: nitroglycerin; isosorbide mononitrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates (NABT Main trial)
Description: nitroglycerin; isosorbide mononitrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates (NABT Main trial)
Description: nitroglycerin; isosorbide mononitrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates (NABT Main trial)
Description: nitroglycerin; isosorbide mononitrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment
Study: NCT02790372

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case conferencing
Description: Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
Study: NCT01339468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: intravenous
Study: NCT02487368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle stimulation pad